These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 6133187)

  • 1. Serum aluminium measurements in renal bone disease.
    Lancet; 1983 May; 1(8334):1168-9. PubMed ID: 6133187
    [No Abstract]   [Full Text] [Related]  

  • 2. Aluminum-related bone disease in mild and advanced renal failure: evidence for high prevalence and morbidity and studies on etiology and diagnosis.
    Smith AJ; Faugère MC; Abreo K; Fanti P; Julian B; Malluche HH
    Am J Nephrol; 1986; 6(4):275-83. PubMed ID: 3777036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aluminum and phosphate.
    Kaye M; Turner M; Ardila M; Wiegmann T; Hodsman A
    Kidney Int Suppl; 1988 Mar; 24():S172-4. PubMed ID: 3163042
    [No Abstract]   [Full Text] [Related]  

  • 4. Aluminium toxicity in dialysis patients: no evidence for a threshold serum aluminium concentration.
    Altmann P
    Nephrol Dial Transplant; 1993; 8 Suppl 1():25-34. PubMed ID: 8389017
    [No Abstract]   [Full Text] [Related]  

  • 5. [Role of aluminium and magnesium effects on initiation and promotion of renal osteodystrophy in patients with chronic renal failure].
    Nakamrua M; Sato N; Tsukamoto Y; Marumo F; Iwanami S
    Nihon Jinzo Gakkai Shi; 1986 Apr; 28(4):421-8. PubMed ID: 3747253
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of fracturing renal osteodystrophy by desferrioxamine.
    Ackrill P; Day JP; Garstang FM; Hodge KC; Metcalfe PJ; Benzo Z; Hill K; Ralston AJ; Ball J; Denton J
    Proc Eur Dial Transplant Assoc; 1983; 19():203-7. PubMed ID: 6878234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of serum aluminium levels for bone accumulation in haemodialyzed patients.
    Costantini S; Giordano R; Vernillo I; Piccioni A; Zapponi GA
    Ann Ist Super Sanita; 1989; 25(3):457-61. PubMed ID: 2624356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of serum aluminum values with tissue aluminum concentration.
    De Broe ME; Van de Vyver FL; Bekaert AB; D'Haese P; Paulus GJ; Visser WJ; Van Grieken R; de Wolff FA; Verbueken AH
    Contrib Nephrol; 1984; 38():37-46. PubMed ID: 6713899
    [No Abstract]   [Full Text] [Related]  

  • 9. The efficacy of various treatment modalities on aluminium associated bone disease.
    Ihle BU; Buchanan MR; Stevens B; Becker GJ; Kincaid-Smith P
    Proc Eur Dial Transplant Assoc; 1983; 19():195-202. PubMed ID: 6348735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adynamic bone disease in kidney failure. Role of aluminum].
    Cohen-Solal ME; Sebert JL; Morinière P; Fournier A
    Rev Rhum Ed Fr; 1993 May; 60(5):361-4. PubMed ID: 8167643
    [No Abstract]   [Full Text] [Related]  

  • 11. Iron overload and bone disease in chronic dialysis patients.
    Van de Vyver FL; Visser WJ; D'Haese PC; De Broe ME
    Contrib Nephrol; 1988; 64():134-43. PubMed ID: 3180820
    [No Abstract]   [Full Text] [Related]  

  • 12. Aluminum and renal bone disease in Australia.
    Dunstan CR; Evans RA
    Kidney Int Suppl; 1986 Feb; 18():S65-9. PubMed ID: 3457999
    [No Abstract]   [Full Text] [Related]  

  • 13. Aluminum in chronic hemodialysis. Possible influence on osteomalacic bone disease.
    Quarello F; Giachino G; Bossi P; Gilli G; Corrao G; Scursatone E; Jeantet A; Bossi R; Coppo R; Piccoli G; Vercellone A
    Minerva Nefrol; 1980; 27(4):635-44. PubMed ID: 7254691
    [No Abstract]   [Full Text] [Related]  

  • 14. Experience with aluminum-associated bone disease in end-stage renal disease patients.
    Joglar FM; Rivera CG; Burgos R; Huffer WE
    Transplant Proc; 1991 Apr; 23(2):1823-4. PubMed ID: 2053166
    [No Abstract]   [Full Text] [Related]  

  • 15. Aluminum accumulation in children on chronic dialysis: predictive value of serum aluminum levels and desferrioxamine infusion test.
    Roodhooft AM; van de Vyver FL; D'Haese PC; van Acker KJ; Visser WJ; de Broe ME
    Clin Nephrol; 1987 Sep; 28(3):125-9. PubMed ID: 3665205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum aluminium concentration and aluminium deposits in bone in patients receiving haemodialysis.
    Charhon SA; Chavassieux PM; Meunier PJ; Accominotti M
    Br Med J (Clin Res Ed); 1985 Jun; 290(6482):1613-4. PubMed ID: 3924189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy of aluminum overload (I).
    Pierides AM; Myli MP
    Contrib Nephrol; 1984; 38():65-77. PubMed ID: 6425013
    [No Abstract]   [Full Text] [Related]  

  • 18. Indirect methods for the diagnosis of aluminum bone disease: plasma aluminum, the desferrioxamine infusion test, and serum iPTH.
    Nebeker HG; Andress DL; Milliner DS; Ott SM; Alfrey AC; Slatopolsky EA; Sherrard DJ; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S96-9. PubMed ID: 3458006
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical study of concerning factors of decreased bone mineral content in hemodialysis patients].
    Kohara N
    Nihon Jinzo Gakkai Shi; 1991 Jun; 33(6):587-96. PubMed ID: 1920939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scalp hair as an indicator of aluminium exposure: comparison to bone and plasma.
    Wilhelm M; Passlick J; Busch T; Szydlik M; Ohnesorge FK
    Hum Toxicol; 1989 Jan; 8(1):5-9. PubMed ID: 2785480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.